<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855202</url>
  </required_header>
  <id_info>
    <org_study_id>Guangdong W C H</org_study_id>
    <nct_id>NCT03855202</nct_id>
  </id_info>
  <brief_title>The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms</brief_title>
  <acronym>BPD</acronym>
  <official_title>The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>yangjie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Women and Children Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchopulmonary dysplasia mainly occurs in premature infants, which is the main cause of
      premature infant death.If children with BPD can survive, they are also prone to complications
      of long-term respiratory diseases such as asthma,that affect the quality of life of BPD
      children. However, there is no effective treatment method for BPD. So,the investigator would
      like to investigate the effect of Intratracheal PS and mononuclaer cells in pretems
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 clinical trial that constitues one time points cohor and three group,each
      group with 80 participants,which receive intratracheal PS and mononuclaer cells,receive
      intratracheal PS,receive intratracheal mononuclaer cells.

        1. Eligibility Criteria:Preterm(gestational age more than 28weeks and less than 37weeks)

        2. Exlusion criteria: Preterm infants with major congenital malformations,chromosomal
           anomalies,inborn errors of metabolism and clinical or laboratory evidence of a
           congenital infection

        3. Demographic Data and Baseline characteristics of the study groups were collected:

      Gestational age(weeks) birth weight(g) gender Cesarean section delivery antenatal steroids
      prolonged rupture of membrane Multiple pregnancies APGAR score at 5 minutes Thrombocytopenia
      before intervention CRP befor intervention(mg/l) TNF-αbefore intervention（pg/ml） 4.Autologous
      cord blood mononuclear cells doses is 25million cells/kg 5.the following are monitored at
      3、7、14、21 days after birth: mortality, incidence of bronchopulmonary dysplasia 5.Long-term
      follow up:in 1m，3m，6m,1y:neurodevelopment,asthma，anemia and physic growth
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 24, 2019</start_date>
  <completion_date type="Anticipated">August 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients who died</measure>
    <time_frame>up to 21 days after birth</time_frame>
    <description>mority rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with neurodevelopmental disorder assessed by Bayley Score</measure>
    <time_frame>up to 1 month, 3 month, 6 months and 1 year</time_frame>
    <description>Long term follow up:in 1 month, 3months,6 months,and 1 years:</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Neonates Premature</condition>
  <condition>Ventilator Support</condition>
  <arm_group>
    <arm_group_label>infusion froup 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infusion group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infusion group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PS,dose is 70mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride installation after 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CBMNC</intervention_name>
    <description>autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg</description>
    <arm_group_label>infusion froup 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PS+CBMNC</intervention_name>
    <description>autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg</description>
    <arm_group_label>infusion group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PS</intervention_name>
    <description>PS,dose is 70mg/kg</description>
    <arm_group_label>infusion group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placeo</intervention_name>
    <description>0.9% sodium chloride installation after 24 hours</description>
    <arm_group_label>Placebol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        twenty-eight weeks to thirty-seven weeks

        Exclusion Criteria:

        Pretem infants with major congenital malformations,chromosomal anomalies,inborn errors of
        metabolism and clinical or laboratory evidence of a congenital infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>36 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Yang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Women and Children Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuxiao Ren, MD</last_name>
    <phone>+8613538984634</phone>
    <email>renzhx1990@163.com</email>
  </overall_contact>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>February 24, 2019</last_update_submitted>
  <last_update_submitted_qc>February 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Women and Children Hospital</investigator_affiliation>
    <investigator_full_name>yangjie</investigator_full_name>
    <investigator_title>Director of Dept of Neonatology</investigator_title>
  </responsible_party>
  <keyword>PS</keyword>
  <keyword>cord blood mononuclaer Cells</keyword>
  <keyword>preterm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

